(Q44530576)

English

Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial

scientific article published on 8 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

substance use disorder

1 reference

based on heuristic

inferred from title

Carsten Hjorthøj

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Christian Gluud

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Merete Nordentoft

6

object named as

M Nordentoft

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

A Fohlmann

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A-M Larsen

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Arendt

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

8 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Psychological Medicine

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1499-1510

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Assessment of client/patient satisfaction: development of a general scale

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Stop Using Stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

A brief motivational intervention for substance misuse in recent-onset psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

A prospective evaluation of adherence to medication in first episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances--systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomize

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

SCAN. Schedules for Clinical Assessment in Neuropsychiatry

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Pharmacological treatment of cannabis dependence

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cannabis use and misuse prevalence among people with psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cannabis use and psychosis: a longitudinal population-based study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cannabis and schizophrenia: results of a follow-up study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Application and results of the Manchester Short Assessment of Quality of Life (MANSA).

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

CCPP-Copenhagen Community Psychiatric Project. Implementation of community mental health centres in Copenhagen: effects of service utilization, social integration, quality of life and positive and negative symptoms.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

CONSORT 2010 changes and testing blindness in RCTs

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Cannabis use and outcome of recent onset psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Reasons for cannabis use in psychosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

21 January 2018

Psychosocial interventions for people with both severe mental illness and substance misuse

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration and interpretation of the Trail Making Test

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting medication noncompliance after hospital discharge among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712002255

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S0033291712002255

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

release_wtef7wgd6zhc5j26tw2aov3jvu

1 reference

https://api.fatcat.wiki/v0/release/wtef7wgd6zhc5j26tw2aov3jvu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44530576&oldid=2026949457"